Skip to main content
Signal8

AVENUE THERAPEUTICS, INC. (ATXI)

Avenue Therapeutics, Inc. functions as a specialized pharmaceutical enterprise, primarily dedicated to innovating and bringing to market medical therapies tailored for critical and intensive care environments within hospitals. Their leading product candidate is intravenous Tramadol, a synthetic opioid with a dual mechanism of action, currently undergoing Phase III clinical trials for the management of severe pain experienced by patients after surgery. Established in 2015, the company's operations are based in New York, New York.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Avenue Therapeutics, Inc. logo

Avenue Therapeutics, Inc.

OTC:ATXIHealthcare
-8.29%$0.2800
Mkt Cap$923K
EV-
Float2.85M
O/S3.29M
VOL3K sh
$ Vol$798
RVOL1.01×
Inst Own-
SI<0.1%
Net Cash/Sh-
Dilution
Avenue Therapeutics, Inc. logoOTC:ATXI$0.2800-8.29%

AVENUE THERAPEUTICS, INC. (ATXI) dilution facts from SEC filings

Snapshot as of Sep 30, 2026, built from 20 SEC filings.

Shelf registration
None on file in the filings reviewed
At-the-market (ATM) program
No active program in the filings reviewed
Warrants outstanding
3 warrant series recorded as outstanding
Most recent offering
None recorded in the filings reviewed

Check another stock for dilution

Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.

Unlock with Signal8 Pro